CJC-1295 with vs without DAC: the half-life difference that changes everything
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- CJC-1295 'with DAC' bonds to albumin in the blood and lasts about a week: its half-life in people was 5.8 to 8.1 days. That is the molecule tested in the 2006 human trials.
- 'CJC-1295 without DAC', also called Mod GRF 1-29, is the same peptide chain minus the albumin-binding lysine. We found no human study of it in PubMed, so its half-life in people has not been published.
- A preparation seized in Norway in 2009, which the analysts described as consistent with a peptide marketed as 'CJC-1295', was a 29-amino-acid peptide, the length of the version without DAC. Drugs@FDA lists no application for CJC-1295, and WADA prohibits it.
Two molecules, one name
Growth-hormone-releasing hormone (GHRH) tells the pituitary to release growth hormone. Its first 29 amino acids, GHRH(1-29), were approved in the US as sermorelin (Geref), for testing the pituitary and later for children with idiopathic growth hormone deficiency; both products were discontinued, and FDA determined in 2013 that this was not for reasons of safety or effectiveness 1. GHRH's weakness as a drug is its short duration of action 2. By 2005, researchers at the Canadian company ConjuChem had published CJC-1295, a long-lasting version 3.
Two different peptides now go by that name. One is the molecule ConjuChem made and that was tested in people 3 2. The other, called 'CJC-1295 without DAC' or Mod GRF 1-29, is the same chain without the albumin-binding part and has no human study in PubMed 4 5. Our encyclopedia keeps them as separate entries, CJC-1295 and Mod GRF 1-29, because they are different molecules with different evidence.
Side by side
From the studies and pages cited below, as of October 28, 2026:
| CJC-1295 with DAC | 'CJC-1295 without DAC' (Mod GRF 1-29) | |
|---|---|---|
| What it is | Tetrasubstituted GHRH(1-29) with a maleimide-carrying lysine added at the end, which bonds to albumin 3 | The same tetrasubstituted GHRH(1-29), without the added lysine 4 |
| Half-life in people | Estimated 5.8 to 8.1 days 2 | No human study found in PubMed 5 |
| Human studies | Two randomised trials in healthy adults (2006) 2, a pulsatility study 6 and a proteomics study 7 | None found in PubMed; it appears there in seized doping material 8 5 |
| Effect on GH | GH raised 2- to 10-fold for 6 days or more; troughs up 7.5-fold, pulses preserved 2 6 | Not measured in people 5 |
| Evidence grade | Medium | Low |
| WADA | Named in S2.2.4 9 | Covered by S2.2.4 as a GHRH analogue, not named 9 |
The chemistry: what DAC means
CJC-1295 is a tetrasubstituted form of GHRH(1-29) with an added lysine at the end of the chain carrying a reactive maleimide group 3. Compared with sermorelin's sequence, the four substitutions are D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27; Mod GRF 1-29 has the same 29 residues and amide end, without the added lysine 4. The maleimide-lysine is what is called the Drug Affinity Complex, or DAC.
The maleimide group bonds to the free thiol on cysteine-34 of albumin, so after injection the peptide circulates attached to albumin. In the 2005 study that introduced it, written by ConjuChem's researchers, albumin conjugates resisted the enzyme dipeptidyl peptidase-IV and remained active on pituitary cells; in rats, CJC-1295 produced four times the growth hormone of unmodified GHRH(1-29) over two hours and was still present in plasma after 72 hours, appearing on albumin from 15 minutes onwards 3. That albumin bond is the difference between the two products.
The 2006 human trials
CJC-1295 was tested in two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, lasting 28 and 49 days. After a single injection under the skin, mean growth hormone rose two- to tenfold for six days or more, and mean IGF-1 rose 1.5- to threefold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days. With repeated doses, IGF-1 stayed above baseline for up to 28 days, and no serious adverse reactions were reported in the trials 2.
A second 2006 study asked whether that sustained exposure flattened the natural rhythm of growth hormone, which is released in pulses. Healthy men aged 20 to 40 had blood drawn every 20 minutes overnight before and one week after an injection. The frequency and size of growth hormone pulses did not change, but trough levels between pulses rose 7.5-fold, mean growth hormone by 46% and IGF-1 by 45% 6. A 2009 proteomics analysis of serum from 11 young men before and one week after an injection found protein changes the authors proposed as possible markers of growth hormone and IGF-1 action 7.
Mod GRF 1-29: the unstudied twin
Mod GRF 1-29 is the tetrasubstituted chain without the DAC lysine, so it has no means of binding albumin 4 3. What it does in people has not been published: a PubMed search on October 28, 2026 found no human study of it, and its one record there is a Danish forensic paper identifying a glycine-extended analogue of it in seized doping material 5 8. We found no published half-life for it in people. Every human number for CJC-1295, the week-long half-life, the IGF-1 rise and the preserved pulses, belongs to the version with DAC 2 6.
The naming problem, documented
In 2009, Norwegian police and customs submitted an unknown preparation for analysis; mass spectrometry found a 29-amino-acid peptide with a C-terminal amide, whose sequence the chemists described as consistent with a peptide then marketed as CJC-1295 10. ConjuChem's CJC-1295 carries an extra lysine after those 29 residues 3, so a 29-residue amide matches the version without DAC 4. The analysts wrote that the substance was readily available and that there was reason to believe it was used in bodybuilding 10. The consequence for buyers is that a vial labelled CJC-1295 may contain either molecule, and the human trial data apply only to one.
That matters for exposure. In the trials, one injection of the DAC version kept growth hormone raised for six days or more 2, while no one has measured how long the version without DAC acts in people 5. A buyer who does not know which molecule is in the vial cannot know which pattern of exposure they are getting.
Why the pulse pattern matters
Growth hormone is normally released in pulses, and that pulsatile pattern is considered important for many of the hormone's effects, which is why the 2006 pulsatility study was designed 6. CJC-1295 with DAC did something in between constant and pulsed release. The pulses kept their frequency and size, but the troughs between them rose 7.5-fold, so total growth hormone exposure went up, and IGF-1 rose 45% 6.
No study has measured what Mod GRF 1-29 does to growth hormone pulses in people, so claims about it producing natural-looking bursts are untested 5.
How to tell which one is in a vial
The two molecules differ in mass, which is how a laboratory can tell them apart. From their formulas (C165H269N47O46 for CJC-1295 with DAC and C152H252N44O42 for Mod GRF 1-29), the average molecular weights are about 3,647.2 and 3,367.9, a difference of about 279 daltons, the added maleimidopropionyl-lysine 4. A genuine certificate of analysis should name the molecule unambiguously, state which version it is, and report a measured mass that matches one figure or the other. A certificate that says only 'CJC-1295', or reports a mass that matches neither, does not tell you what you have. Our COA Decoder explains how mass checks work, and our guide to spotting a fake certificate shows a worked example.
The ipamorelin pairing
Mod GRF 1-29 is often discussed alongside ipamorelin, a ghrelin-receptor agonist. A PubMed search on October 28, 2026 for papers naming both CJC-1295 and ipamorelin returned 11 records, all reviews or doping-analysis papers and no trial of the pair 5, and Drugs@FDA lists no application for either 11. Our blends hub sets out what a CJC-1295 and ipamorelin mix contains, and our article on the stack covers the evidence on each component.
What the animal work added
In mice lacking the GHRH gene, CJC-1295 given daily from one week of age for five weeks produced normal body weight and length; dosing every 48 hours kept bone length normal without fully normalising growth, and every 72 hours improved growth without normalising it 12. Because CJC-1295 bonds to plasma proteins, it is hard to detect by mass spectrometry; a racing laboratory developed a method to confirm it in horse plasma at concentrations as low as 180 pg/mL 13.
Where the approved GHRH drugs fit
CJC-1295 is one of several attempts to make GHRH last longer. Sermorelin, GHRH(1-29) itself, was approved in the US as Geref and later discontinued 1. Tesamorelin, a GHRH analogue, is approved as EGRIFTA WR to reduce excess abdominal fat in adults with HIV and lipodystrophy 14. CJC-1295 has no FDA application 11. Our comparison of somatropin and sermorelin explains how a releasing hormone differs from growth hormone itself.
Who uses it, and why
A study of 23 discussion threads on nine bodybuilding forums found women using CJC-1295 for weight loss, muscle, younger-looking skin, sleep and injury healing, usually alongside other performance and image drugs, and worrying about how sex differences in growth hormone might change its effects 15. None of those uses has been tested in the studies cited here. The human studies above measured hormone levels, not body composition, sleep or healing 2 6.
Safety and status
Drugs@FDA lists no application for CJC-1295 11. FDA's safety-risks page (content current as of April 22, 2026) lists CJC-1295 among substances nominated for compounding and withdrawn, and records serious adverse events associated with it, including increased heart rate and a systemic vasodilatory reaction, a possible immunogenicity risk for certain routes, and limited clinical data 16. The longest human study ran 49 days 2, so effects of raising growth hormone and IGF-1 for longer are unknown. WADA's 2026 Prohibited List names CJC-1295 among GHRH analogues under S2.2.4, prohibited at all times; Mod GRF 1-29 is not named but is a GHRH analogue 9 4.
The bottom line
As of October 28, 2026, 'CJC-1295 with DAC' is a long-acting GHRH analogue with small 2006 studies in healthy adults and a week-long half-life 2. 'CJC-1295 without DAC' is Mod GRF 1-29, a related peptide with no human study in PubMed 5. They are not interchangeable, the name on a vial does not reliably tell you which you have 10, and neither has an FDA application 11. If you see a claim about 'CJC-1295', the first question to ask is which of the two it is about. Our comparison of tesamorelin and CJC-1295 shows what a GHRH analogue that did complete approval looks like.
Frequently asked questions
What is the difference between CJC-1295 with and without DAC?
CJC-1295 with DAC has an added lysine carrying a group that bonds to albumin, giving a half-life of 5.8 to 8.1 days in people. Without DAC, the peptide (Mod GRF 1-29) cannot bind albumin and has no human study in PubMed.
Is Mod GRF 1-29 the same as CJC-1295?
It is CJC-1295's 29-residue chain without the albumin-binding DAC lysine. The human trials of CJC-1295 used the version with DAC.
What is the half-life of CJC-1295 without DAC?
No published study has measured it in people; a PubMed search in October 2026 found none.
Is CJC-1295 approved or legal?
Drugs@FDA lists no application for it, its US compounding nomination was withdrawn, and WADA prohibits it.
Related on Grey Peptides
Sources
- U.S. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness (NDA 19-863 ampules, December 28, 1990; NDA 20-443 vials, September 26, 1997). Federal Register 78:14096, March 4, 2013 (Docket FDA-2012-P-1071). Federal Register notice
- Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805. PMID: 16352683
- Jetté, L., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-8. PMID: 15817669
- Grey Peptides encyclopedia entries for CJC-1295 (sequence ending Lys(MPA)-NH2, formula C165H269N47O46) and Mod GRF 1-29 (the same 29 residues ending Arg-NH2, formula C152H252N44O42), with sermorelin's sequence for the substitutions; average masses computed from the formulas. Read October 28, 2026.
- PubMed searches, October 28, 2026: "mod GRF 1-29" OR "modified GRF (1-29)" OR "modified GRF 1-29" (1 record: the Danish forensic analysis of seized doping material cited below); CJC-1295[tiab] AND ipamorelin[tiab] (11 records: reviews and a doping-analysis paper, no trial of the pair).
- Ionescu, M., et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 91(12), 4792-7. PMID: 17018654
- Sackmann-Sala, L., et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res, 19(6), 471-7. PMID: 19386527
- Gajda, P. M., et al. (2019). Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal, 11(2), 350-354. PMID: 30136411
- World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S2.2.4, growth hormone releasing factors, including GHRH and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin); prohibited at all times. Read October 28, 2026. WADA
- Henninge, J., et al. (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal, 2(11-12), 647-50. PMID: 21204297
- FDA. Drugs@FDA via openFDA: no application for CJC-1295 or ipamorelin; sermorelin (GEREF, NDA 019863 and 020443, discontinued); tesamorelin (BLA 022505). Searched October 28, 2026.
- Alba, M., et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab, 291(6), E1290-4. PMID: 16822960
- Timms, M., et al. (2019). A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal, 11(8), 1248-1257. PMID: 30938069
- Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information (revised 3/2025), section 1. DailyMed set 839334d3, version 2; read October 28, 2026. DailyMed
- Van Hout, M. C., et al. (2016). Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse, 51(1), 73-84. PMID: 26771670
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026): CJC-1295 in the table of substances nominated but withdrawn, with its listed risks. Read October 28, 2026. FDA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead